Logo image of COGT

COGENT BIOSCIENCES INC (COGT) Stock Fundamental Analysis

USA - NASDAQ:COGT - US19240Q2012 - Common Stock

14.82 USD
+0.1 (+0.68%)
Last: 11/7/2025, 8:00:01 PM
14.42 USD
-0.4 (-2.7%)
After Hours: 11/7/2025, 8:00:01 PM
Fundamental Rating

1

COGT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 535 industry peers in the Biotechnology industry. The financial health of COGT is average, but there are quite some concerns on its profitability. COGT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year COGT has reported negative net income.
In the past year COGT has reported a negative cash flow from operations.
In the past 5 years COGT always reported negative net income.
COGT had a negative operating cash flow in each of the past 5 years.
COGT Yearly Net Income VS EBIT VS OCF VS FCFCOGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of COGT (-74.40%) is worse than 64.55% of its industry peers.
Looking at the Return On Equity, with a value of -131.89%, COGT is doing worse than 61.19% of the companies in the same industry.
Industry RankSector Rank
ROA -74.4%
ROE -131.89%
ROIC N/A
ROA(3y)-52.46%
ROA(5y)-51.99%
ROE(3y)-64.47%
ROE(5y)-60.7%
ROIC(3y)N/A
ROIC(5y)N/A
COGT Yearly ROA, ROE, ROICCOGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

COGT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COGT Yearly Profit, Operating, Gross MarginsCOGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for COGT has been increased compared to 1 year ago.
Compared to 5 years ago, COGT has more shares outstanding
COGT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COGT Yearly Shares OutstandingCOGT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COGT Yearly Total Debt VS Total AssetsCOGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.47 indicates that COGT is not a great score, but indicates only limited risk for bankruptcy at the moment.
COGT has a Altman-Z score of 2.47. This is in the better half of the industry: COGT outperforms 68.28% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that COGT is not too dependend on debt financing.
COGT's Debt to Equity ratio of 0.28 is on the low side compared to the rest of the industry. COGT is outperformed by 70.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z 2.47
ROIC/WACCN/A
WACCN/A
COGT Yearly LT Debt VS Equity VS FCFCOGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 4.19 indicates that COGT has no problem at all paying its short term obligations.
COGT's Current ratio of 4.19 is in line compared to the rest of the industry. COGT outperforms 48.32% of its industry peers.
COGT has a Quick Ratio of 4.19. This indicates that COGT is financially healthy and has no problem in meeting its short term obligations.
COGT has a Quick ratio (4.19) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 4.19
COGT Yearly Current Assets VS Current LiabilitesCOGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

COGT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.02%, which is quite impressive.
EPS 1Y (TTM)27.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

COGT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.96% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-15.02%
EPS Next 2Y1.98%
EPS Next 3Y15.13%
EPS Next 5Y19.96%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COGT Yearly Revenue VS EstimatesCOGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
COGT Yearly EPS VS EstimatesCOGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COGT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COGT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COGT Price Earnings VS Forward Price EarningsCOGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COGT Per share dataCOGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

COGT's earnings are expected to grow with 15.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.98%
EPS Next 3Y15.13%

More info and screens

0

5. Dividend

5.1 Amount

COGT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COGENT BIOSCIENCES INC

NASDAQ:COGT (11/7/2025, 8:00:01 PM)

After market: 14.42 -0.4 (-2.7%)

14.82

+0.1 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-17 2025-11-17/bmo
Inst Owners104.7%
Inst Owner Change0.47%
Ins Owners0.04%
Ins Owner Change0%
Market Cap2.07B
Revenue(TTM)N/A
Net Income(TTM)-204.47M
Analysts81.05
Price Target22.44 (51.42%)
Short Float %11.8%
Short Ratio8.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.16%
Min EPS beat(2)11.44%
Max EPS beat(2)12.87%
EPS beat(4)3
Avg EPS beat(4)23.39%
Min EPS beat(4)-10.87%
Max EPS beat(4)80.14%
EPS beat(8)3
Avg EPS beat(8)4.79%
EPS beat(12)5
Avg EPS beat(12)3.15%
EPS beat(16)5
Avg EPS beat(16)-2.5%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.91%
PT rev (3m)22.22%
EPS NQ rev (1m)1.06%
EPS NQ rev (3m)-3.12%
EPS NY rev (1m)-0.48%
EPS NY rev (3m)-4.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.35
P/tB 13.35
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.67
OCFYN/A
SpS0
BVpS1.11
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.4%
ROE -131.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.46%
ROA(5y)-51.99%
ROE(3y)-64.47%
ROE(5y)-60.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 4.19
Altman-Z 2.47
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)321.08%
Cap/Depr(5y)421.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.17%
EPS Next Y-15.02%
EPS Next 2Y1.98%
EPS Next 3Y15.13%
EPS Next 5Y19.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.95%
EBIT Next 3Y13.23%
EBIT Next 5Y16.58%
FCF growth 1Y-64.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.67%
OCF growth 3YN/A
OCF growth 5YN/A

COGENT BIOSCIENCES INC / COGT FAQ

What is the fundamental rating for COGT stock?

ChartMill assigns a fundamental rating of 1 / 10 to COGT.


What is the valuation status of COGENT BIOSCIENCES INC (COGT) stock?

ChartMill assigns a valuation rating of 0 / 10 to COGENT BIOSCIENCES INC (COGT). This can be considered as Overvalued.


What is the profitability of COGT stock?

COGENT BIOSCIENCES INC (COGT) has a profitability rating of 0 / 10.